Zevalin<sup>TM</sup>:一种放射免疫治疗新药

Zevalin^TM:一种放射免疫治疗新药

文章导航 > 国际放射医学核医学杂志 > 2002, 26 > 5: (225-227)

引用本文:

Citation:

Zevalin^TM:一种放射免疫治疗新药

Department of Nuclear Medicine, Shanghai 6th People's Hospital, Shanghai 2000233, China
CLC number: R817.5

摘要: 放射免疫治疗是放射性核素治疗的重要组成和研究的重点之一。Zevalin^TM第一个得到FDA批准的用于治疗复发或顽固性低度恶性非霍奇金氏淋巴瘤的放射免疫治疗制剂。本文综述了该制剂的组成、治疗方案、药理作用机制、辐射剂量和临床试验结果等方面的内容。
- 放射免疫治疗 /
- 非霍奇金氏淋巴瘤 /
- 90-钇 /
- CD20抗原 /
- Zevalin
Abstract: Radioimmunotherapy is a major component of radionuclide therapy and always being the main field of re-search.Zevalin^TM is the first FDA marketing approved radioimmunotherapy agent which is indicated for the treatment of relapsed or refractory low grade non-Hodgkin's lymphoma.In this review,the component,therapeutic regimen,pharmacological mechanism,radiation dosage and clinical experiment result of Zevalin^TM are described respectively.
- radioimmunotherapy /
- non-Hodgkin's lymphoma /
- Yittrium-90 /
- CD20 antigen /
- Zevalin
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Srivastava S, Dadachova E. Recent advances in radionuclide therapy[J]. Semin Nucl Med, 2001, 31(4):330-341.
[2]	Krasner C, Joyce RM. Zevalin:90-Yttrium labeled anti-CD20(Ibritumomabtiuxetan), a new treatment for non-Hodgkin's lymphoma[J]. Curr Pharm Biotechol, 2001, 2(4):341-349.
[3]	Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with ⁹⁰Y labelled anti-CD20 monoclonal antibody[J]. J Nucl Med, 2002, 43(2):267-272.
[4]	Hainsworth JD. Monoclonal antibody therapy in lymphoid malignancies[J]. Oncologist, 2000, 5(5):376-384.
[5]	Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results froma phase Ⅲ prospectively randomized controlled trial Zevalin^TM radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma[J]. Critical Revi Oncol Hematol,2001, 39(2):181-194.
[6]	Janakiraman N, Gutheil J, Schilder RJ, et al. Phase Ⅰ/Ⅱ trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refratory CD20(+) B-cell non-Hodgkin's lymphoma[J]. J Clin Oncol, 1999, 17(12):3793-3803.

[1]	高云朝 . 恶性胶质瘤的放射免疫治疗. 国际放射医学核医学杂志, 2004, 28(4): 149-152.
[2]	陈立波 , 朱瑞森 . Bexxar治疗非霍奇金淋巴瘤的研究现状. 国际放射医学核医学杂志, 2005, 29(2): 67-70.
[3]	崔瑞雪 , 卢倜章 . ⁹⁰Y在肿瘤治疗中的应用. 国际放射医学核医学杂志, 1996, 20(5): 208-211.
[4]	杨连君 , 司晓辉 , 隋延仿 , 陈志南 , 管昌田 . ⁹⁰Y标记单克隆抗体导向治疗肿瘤. 国际放射医学核医学杂志, 1996, 20(5): 205-207.
[5]	李敏杰 . 胰腺癌的放射免疫治疗进展. 国际放射医学核医学杂志, 2003, 27(4): 154-156.
[6]	田嘉禾 . 关于放射免疫治疗的新思考. 国际放射医学核医学杂志, 1997, 21(z1): 249-252.
[7]	田源 , 张良安 . 放射免疫治疗中的α核素微剂量研究. 国际放射医学核医学杂志, 2006, 30(1): 39-41.
[8]	任均田 , 林学颜 . 放射免疫显像与治疗的应用进展. 国际放射医学核医学杂志, 1995, 19(2): 57-59.
[9]	查林 , 冯世斌 , 李前伟 . 非霍奇金淋巴瘤的CD20分子显像及靶向治疗研究进展. 国际放射医学核医学杂志, 2010, 34(5): 269-273. doi: 10.3760/cma.j.issn.1673-4114.2010.05.004
[10]	杨卫东 , 汪静 . 肿瘤核素靶向治疗新进展. 国际放射医学核医学杂志, 2015, 39(1): 19-24, 36. doi: 10.3760/cma.j.issn.1673-4114.2015.01.006